MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehw233

Медицинская библиотека · European heart journal · 2016

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

Bassand Jean-Pierre, Accetta Gabriele, Camm Alan John, Cools Frank, Fitzmaurice David A, Fox Keith A A, Goldhaber Samuel Z, Goto Shinya, Haas Sylvia, Hacke Werner, Kayani Gloria, Mantovani Lorenzo G, Misselwitz Frank, Ten Cate Hugo, Turpie Alexander G G, Verheugt Freek W A, Kakkar Ajay K, GARFIELD-AF Investigators

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year.

METHODS AND

RESULTS

GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death.

CONCLUSION

The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death.

CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.

Для цитирования: Bassand Jean-Pierre, Accetta Gabriele, Camm Alan John, Cools Frank, Fitzmaurice David A, Fox Keith A A, Goldhaber Samuel Z, Goto Shinya, Haas Sylvia, Hacke Werner, Kayani Gloria, Mantovani Lorenzo G, Misselwitz Frank, Ten Cate Hugo, Turpie Alexander G G, Verheugt Freek W A, Kakkar Ajay K, GARFIELD-AF Investigators. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.. European heart journal. 2016. DOI: 10.1093/eurheartj/ehw233.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.